injectables

FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers

FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers

Galderma has received U.S. Food and Drug Administration (FDA) approval of two new Restylane products for the treatment of nasolabial folds (NLF) in patients over the age of 21. Restylane Refyne is approved for the treatment of moderate to severe facial wrinkles and folds, and Restylane Defyne for the treatment of moderate to severe, deep facial wrinkles and folds.

Energy-Based Treatments Safe After PMMA Injections

Energy-Based Treatments Safe After PMMA Injections

In a recent study, researchers Douglas C. Wu, MD, et al, evaluated the safety and histopathological effects of different laser, light and ultrasound modalities on skin previously injected with a polymethylmethacrylate (PMMA) filler (Bellafill, Suneva Medical).

Bellafill is a soft tissue dermal filler composed of non-resorbable microspheres, suspended in a water-based carrier gel with 3.5% bovine collagen; it is FDA approved for the correction of nasolabial folds and atrophic facial acne scars.

Restylane Turns 20

Galderma is celebrating 20 years of Restylane with new packaging and a new, more ergonomic syringe design.
Restylane Turns 20

Though silicone- and then collagen-based dermal fillers have been used since the 1940s to fill out facial defects, it was the introduction of hyaluronic acid (HA)-based dermal fillers that brought these treatments to the main­­stream. “HA fillers completely changed cosmetic medicine,” says facial plastic surgeon Steven Dayan, MD, clin­ical assistant professor at the University of Illinois. “They don’t just fill lines; they actually give volume back to the face. They also have a more natural feel than collagen and offer reversibility that is reliable.

Less Painful Injections

Main Image: 
Less Painful Injections

The INViSIBLE NEEDLE from TSK Laboratory is 33% thinner than a 30g needle. The small diameter reduces pain during neurotoxin injections and lowers the risk of hematoma. Additional features include the company’s patented Low Dead Space (LDS) Hub, designed to reduce the amount of space left behind in the needle hub, which saves up to 0.08ml of product; and external threading for a tighter luer-lock connection.

Contact: 604.269.3490, www.tsklab.nl.

No, don't share this with BeautyEtc
Article free tagging: 
Articles: 

Dermal Filler Treatments Continue to Gain in Popularity

Botulinum toxin injections remain the most popular noninvasive cosmetic procedure, but as they dipped slightly from 2014 to 2015, hyaluronic acid-based dermal filler treatments rose, according to the results of the newly released 2015 International Society of Aesthetic Plastic Surgery (ISAPS) Global Procedural Survey.
The three most popular surgical procedures worldwide include:

Revance to Commence Phase 3 Toxin Trials

Biotechnology company Revance Therapeutics has announced the completion of its Type B/pre-IND/pre-Phase 3 meeting with the U.S. Food and Drug Administration (FDA) regarding injectable DaxibotulinumtoxinA (RT002) for glabellar lines. The company will be moving forward with an Investigational New Drug (IND) submission for a Phase 3 clinical program for RT002 in glabellar lines as well as other supportive studies required for Biologics License Application (BLA) filing.